Trademark Details For ULTRA GARLITE (Serial Number 75927421)

  •  Home
  •  Print
ULTRA GARLITE
1
5
3
0
Serial Number  United States - USPTO 75927421
Registration Number 2473232
Mark
ULTRA GARLITE
Filing Date Feb-25-2000
Status
Registered  
REGISTERED A.. (800)
REGISTERED AND RENEWED
Attorney Name
TTAB
0




005Pharmaceuticals

U.S Class(es): 006, 018, 044, 046, 051, 052

Class Status: Active

First Use: Apr-1994

First Use in Commerce: Apr-1994





Correspondences

NameRoss Q. Panko
AddressArent Fox LLP 1717 K Street, NW Washington DC 20006-5344

Prosecution History

DateDescription
Action Tags    
Action tags indicate key events in the prosecution history. View details of the related office action file by clicking on the icons.
Code
Jul-27-2000ASSIGNED TO EXAMINER   DOCKD
Jul-31-2000NON-FINAL ACTION MAILED   CNRTF
Aug-24-2000CORRESPONDENCE RECEIVED IN LAW OFFICE   CRFAI
Jan-09-2001APPROVED FOR PUB - PRINCIPAL REGISTER   CNSAO
Apr-25-2001NOTICE OF PUBLICATION   NPUBO
May-08-2001PUBLISHED FOR OPPOSITION   PUBOA
Jul-31-2001REGISTERED-PRINCIPAL REGISTER   R.PRA
Dec-22-2006TEAS SECTION 8 & 15 RECEIVED   E815I
Feb-14-2007CASE FILE IN TICRS   CFITO
Jun-18-2007PAPER RECEIVED   MAILI
Sep-26-2007REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.   C15AO
Aug-12-2008TEAS CHANGE OF CORRESPONDENCE RECEIVED   TCCAI
Feb-01-2011TEAS SECTION 8 & 9 RECEIVED   E89RI
Feb-02-2011CASE ASSIGNED TO POST REGISTRATION PARALEGAL   APREA
Feb-25-2011REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED   89AGO
Feb-25-2011REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)   RNL1Q
May-03-2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED   REAPI
May-03-2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED   ARAAI
Jul-31-2020COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED   REM2E
Jun-14-2021TEAS SECTION 8 & 9 RECEIVED   E89RI
Oct-26-2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL   APREA
Oct-26-2021REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED   89AGO
Oct-26-2021REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)   RNL2Q
Oct-26-2021NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED   NA89E